Mangalam Drugs And Organics Limited — Results, 07-08-2025: Integrated Filing- Financial

Here's a summary of Mangalam Drugs and Organics Limited's latest financial results:

1) **Revenue Performance:** Mangalam Drugs and Organics (MDOL) reported a **25.19% YoY drop** in total operating revenue for the quarter, landing at **Rs 57.35 Cr** compared to Rs 76.54 Cr in the same period last year. The company operates solely in "Manufacturing of Bulk Drugs."

2) **Profitability and EPS:** This sharp revenue decline led to a significant swing from profit to loss. MDOL posted a **net loss of Rs 13.80 Cr** for the quarter, a stark contrast to the Rs 2.68 Cr net profit reported in the same quarter last year. Basic EPS stood at **(Rs 8.72)**. Operating profitability (before interest and tax) turned negative, indicating core business struggles.

3) **Operational Costs:** While some expenses like material costs and other operating costs saw absolute declines, these reductions were insufficient to offset the substantial revenue drop, leading to operational inefficiencies.

4) **Key Metrics:** The company recorded negative EBITDA for the quarter, reflecting the challenging operational environment.

5) **Management Commentary / Strategic Outlook:** The company has announced a board meeting where it reviewed and approved the results. MDOL is also pursuing a scheme of merger by absorption with Mangalam Laboratories Private Limited and Shri JB Pharma Private Limited. This scheme awaits National Company Law Tribunal approval, with a meeting for creditors and shareholders scheduled for August 12, 2025, which could reshape future operations.

7) **Final Takeaway:** The latest results reflect a challenging quarter with significant operational headwinds and a sharp decline in financial performance. Investors should monitor the progress of the proposed merger as a potential catalyst for future changes, but current trends signal weak momentum.